AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

American investors might not have to trade in the company's ADSes in the future. Trading in AstraZeneca's (NASDAQ: AZN) ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

CEO Pascal Soriot has not hidden his annoyance at taxes and regulations the pharmaceutical firm have to navigate ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times ...

FTSE 100 giant AstraZeneca is considering moving its listing to the US, marking a potential further blow to the health of ...

ADRs rose 2.2% following a Times report that CEO Sir Pascal Soriot has privately expressed interest in moving the company’s stock market listing to the United States.